Inspire Medical Systems (NYSE:INSP) (“Inspire”) said it has secured positive coverage policies for its Inspire neurostimulation therapy, intended to treat obstructive sleep apnea, from an additional five Blue Cross Blue Shield Association healthcare plans.
These plans include Blue Cross Blue Shield of Mississippi, BCBS Regence, Premera Blue Cross, BCBS of Kansas, and BCBS of Massachusetts. BCBS of Mississippi covers approximately 590,000 members and took effect January 1, 2019. Taking effect Feb. 1, 2019 were:
- BCBS Regence, which covers about 2.6 million members across Washington, Oregon, Idaho, and Utah.
- Premera Blue Cross, the largest health plan in the Pacific Northwest covering over 2.1 million members in Washington and Alaska.
- BCBS of Kansas, which covers approximately 560,000 members.
Coverage by BCBS of Massachusetts, which has about 2.6 million members, will take effect May 1, 2019.
There have now been eight positive coverage policies issued by BCBSA healthcare plans following Blue Cross Blue Shield Association’s Evidence Street January 7, 2019 report, which stated that there is sufficient evidence to determine that Inspire therapy results in a meaningful improvement in net health outcomes for patients meeting specified criteria. These eight Inspire therapy coverage policies comprise approximately 16.6 million members, or 17%, of the total 97 million members currently covered under the Blue Cross Blue Shield Association healthcare plans.
“We are very pleased that regional Blue Cross Blue Shield plans continue to establish positive coverage policies for Inspire therapy in such a short time period following the Evidence Street report,” said Inspire Medical CEO Tim Herbert. “We will continue to work with physicians and medical centers to develop additional positive coverage policies across the 36 BCBS companies in the United States.”